louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06039046: Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients
Official title: Inside Liposarcoma Clinical Trials: Patient Experiences Shared While Undergoing Clinical Trials
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Liposarcoma
Keywords: Liposarcoma
Lead sponsor: Power Life Sciences Inc.
Sponsor class: INDUSTRY
First posted: 2023-09-15
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: People with liposarcoma who are actively considering enrolling in an observational clinical trial, but have not yet completed enrollment and randomization.

Brief summary: The study seeks to delve into the firsthand experiences of patients diagnosed with liposarcoma who partake in a separate clinical research featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals.

By joining this clinical study, individuals have the unique opportunity to contribute to the betterment of future liposarcoma patients and play an active role in advancing medical research.


Eligibility criteria: Inclusion Criteria:

* Patient has self-identified as planning to enroll in a clinical research
* Patient has been diagnosed with liposarcoma
* Patient is a minimum of 18 years or older

Exclusion Criteria:

* Patient does not understand, sign, and return consent form
* Inability to perform regular electronic reporting
* Patient is pregnant

Primary outcomes:
measure: Number of patients who decide to participate in a liposarcoma clinical study
timeFrame: 3 months
measure: Rate of patients who remain in liposarcoma clinical study to trial completion
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: Power Life Sciences
state: California
Study officials:
affiliation: Power Life Sciences
name: Michael B Gill
role: STUDY_DIRECTOR
References:
citation: Chen M, Yang J, Zhu L, Zhou C, Zhao H. Primary intrathoracic liposarcoma: a clinicopathologic study and prognostic analysis of 23 cases. J Cardiothorac Surg. 2014 Jul 4;9:119. doi: 10.1186/1749-8090-9-119.
citation: Marino-Enriquez A, Hornick JL, Dal Cin P, Cibas ES, Qian X. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. Cancer Cytopathol. 2014 Feb;122(2):128-37. doi: 10.1002/cncy.21362. Epub 2013 Nov 12.
citation: Rossouw DJ, Cinti S, Dickersin GR. Liposarcoma. An ultrastructural study of 15 cases. Am J Clin Pathol. 1986 Jun;85(6):649-67. doi: 10.1093/ajcp/85.6.649.
Clinical trial NCT06275646: Comparison Of Outcome Of Different Layers in Hypospadias Surgery
Official title: Comparison Of Outcome Of Autologus Platelet Rich Plasma Membrane Plus Dartos Flap Versus Simple Dartos Flap In Hypospadias Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hypospadias
Keywords: Hypospadias
platelet rich plasma
distal penile hypospadias
Lead sponsor: Children Hospital and Institute of Child Health, Lahore
Sponsor class: OTHER
First posted: 2024-02-23
Enrollment: 220
Sex: MALE
Minimum age (years): 6
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: randomized control trial
Primary purpose: TREATMENT

Brief summary: To compare the outcome of applying autologous platelet-rich plasma membrane layer and dartos fascial flap versus only dartos fascial flap in mid and distal penile hypospadias surgery. A total of 220 patients fulfilling the selection criteria were admitted after taking informed consent. Cases were randomly divided into groups A and B using a random generator of the Excel program. In group A, dartos flap and PRP sheet layer were applied and in group B, only a preputial dartos fascial flap was applied

Detailed description: Objective To compare the outcome of application of autologous platelet-rich plasma membrane layer and dartos fascial flap versus only dartos fascial flap in mid and distal penile hypospadias surgery.

Methods This randomized controlled trial was conducted at Pediatric General surgical department, the Children's hospital and the University of Child health, Lahore for the period of 12 months. Non probability, purposive sampling was used for data collection and randomization was done to assign the treatment. Total of 220 patients fulfilling the selection criteria were admitted after taking an informed consent. Cases were randomly divided into two groups A and B using random generator of Excel program. In group-A, dartos flap and PRP sheet layer was applied and in group-B, only a preputial dartos fascial flap was applied.

Eligibility criteria: Inclusion Criteria:

* patients (Age 6months to12 years) with mid, distal penile or sub coronal hypospadias having minimal chordae were included in the study

Exclusion Criteria:

* Patients having proximal hypospadias, moderate to severe chordae, previously operated cases, a preoperative androgens treatment (for example in penoscrotal hypospadias and small sized phallus) were excluded from study

Primary outcomes:
measure: wound infectiom
timeFrame: 30 days
measure: frequency of glans dehiscence
timeFrame: 30 days
measure: frequency of meatal stenosis
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: The Children Hospital
state: Punjab
Study officials:
affiliation: CHUCHS
name: Muhammad Adeel Ashiq, M.S
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04563546: Acute Coronary Syndrome KCMC
Official title: Community and Physician Perceptions of Chest Pain and Prevalence of Acute Coronary Syndrome Among HIV-infected and -Uninfected Patients in Moshi, Tanzania
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Acute Coronary Syndrome
Lead sponsor: Duke University
Sponsor class: OTHER
First posted: 2020-09-24
Enrollment: 641
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to develop a quality improvement intervention to address barriers to evidence-based acute coronary syndrome (ACS) care in northern Tanzania. Patients who presented to Kilimanjaro Christian Medical Center (KCMC) will be asked to complete a survey about barriers and facilitators of health care. In addition the survey will be administered to all providers, policymakers, and administrators participating in in-depth interviews. Data from this survey will be used to develop a quality improvement intervention that will be piloted by KCMC staff. Six months after the pilot program is implemented providers, patients, and administrators will be interviewed for their perspectives on the program.


Eligibility criteria: Inclusion Criteria:

* 18 years or older
* symptoms related to acute coronary syndrome
* myocardial infarction
* clinically sober
* able to communicate in Swahili or English

Exclusion Criteria:

* medically unstable
* have a deteriorating condiction
* too critically ill to participate

Primary outcomes:
measure: Acceptability as Measured by the Acceptability of Intervention Measure (AIM)
timeFrame: Initial ED visit (baseline)
Secondary outcomes:
measure: Number of Participants Presenting With Chest Pain or Shortness of Breath Who Undergo ECG and Cardiac Biomarker Testing During Their ED Stay
timeFrame: Initial ED visit (baseline)
measure: Survival of Participants With Acute Coronary Syndrome (ACS) at 30 Days After Enrollment
timeFrame: 30 days after enrollment
measure: Number of Participants With Acute Coronary Syndrome (ACS) Taking Aspirin at Baseline
timeFrame: Initial ED visit (baseline)
measure: Number of Participants With Acute Coronary Syndrome (ACS) Taking Aspirin 30 Days After Enrollment
timeFrame: 30 days after enrollment
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University Hospital
state: North Carolina
Study officials:
affiliation: Duke University Hospital
name: Julian Hertz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03104946: To Research the Relation Between Neonatal Morbidities and Poor Outcome in Preterm Infants
Official title: Clinical Research on the Predictive Effect of Neonatal Morbidities on the Poor Outcomes to Very Low Birth-weight and Extremely Low Birth-weight Infants
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Preterm Infant
Morbidity;Infant
Outcome, Fatal
Lead sponsor: Guangdong Women and Children Hospital
Sponsor class: OTHER
First posted: 2017-04-07
Enrollment: 834
Sex: ALL
Minimum age (years): 1
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: From November 2014 to October 2015, a multi-centers retrospective study was conducted to collect compliance, and 8 three-level hospitals from China were included. The infants survived to a postmenstrual age of 36 week with birth weight less than 1500g and without congenital disease.

Brief summary: From November 2014 to October 2015, a multi-centers retrospective study was conducted to collect compliance, and 8 three-level hospitals from China were included. The infants survived to a postmenstrual age of 36 week with birth weight less than 1500g and without congenital disease. The birth weight, gestational age, morbidities and poor outcomes( death, cerebral palsy, cognitive, et al) were recorded. Data were analyzed with Chi-square test to observe the relationship between morbidities and poor outcomes. And the predictive effect on the number of the top three morbidities were analyzed by Logistic regression analysis.


Eligibility criteria: Inclusion Criteria:

From November 2014 to October 2015, a multi-centers retrospective study was conducted to collect compliance, and 8 three-level hospitals from China were included. The infants survived to a postmenstrual age of 36 week with birth weight less than 1500g.

Exclusion Criteria:

The very low birth weight infants didn't have any congenital disease.

Primary outcomes:
measure: cognitive delay
timeFrame: 1 year
measure: hearing impairment
timeFrame: 1 year
measure: visual impairment
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF; Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA. 2003 Mar 5;289(9):1124-9. doi: 10.1001/jama.289.9.1124.
citation: Rao YB, Yang J, Cao B, Chen DM, Gao PM, Zhong Q, Li MX, Gao JH, Chen YJ, Zhong XM, Ren ZX. [Predictive effect of neonatal morbidities on the poor outcomes at 12 months corrected age in very low birth weight premature infants]. Zhonghua Er Ke Za Zhi. 2017 Aug 2;55(8):608-612. doi: 10.3760/cma.j.issn.0578-1310.2017.08.012. Chinese.
Clinical trial NCT05686746: Use of Baricitenib to Maintain of Remission
Official title: Uses of Baricetinib 4 mg or 2mg Versus MMF to Maintain Lupus Remission Randomized Controlled Trial: Outcomes Over 2 Years
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Lupus or SLE
Nephritis
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2023-01-17
Enrollment: 80
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Baricitinib a selective Janus kinase (JAK) inhibitors 1\&2 have been recognized as a potential therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no JAK inhibitor studies have been conducted in lupus nephritis (LN) maintain remission to date.

Detailed description: Baricitinib a selective Janus kinase (JAK) inhibitors 1\&2 have been recognized as a potential therapeutic option in systemic lupus (SLE), also known Baricitinib, a JAK inhibitor, has demonstrated efficacy and safety in the treatment of dermatitis and arthritis 1 ; however, no JAK inhibitor studies have been conducted in lupus nephritis (LN) maintain remission to date. Objectives: To assess the efficacy and safety of Baricitinib in patients (pts) with LN by dose 4mg versus 2 mg versus MMF 1 gm daily dose.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Lupus nephritis Disease
* Must be able to swallow tablets
* lupus nephritis in remission

Exclusion Criteria:

* antiphospholipid syndrome disease
* thrombosis history
* sever anemia, leukopenia or thrombocytopenia
* impaired liver and renal function

Primary outcomes:
measure: proteins creatinine ratio
timeFrame: 3 months
measure: proteins creatinine ratio
timeFrame: 6 months
measure: proteins creatinine ratio
timeFrame: 1 year
Secondary outcomes:
measure: complement 3
timeFrame: 3 months
measure: complement 3
timeFrame: 6 months
measure: complement 3
timeFrame: 1 year
measure: anti ds DNA
timeFrame: 3 months
measure: anti ds DNA
timeFrame: 6 months
measure: anti ds DNA
timeFrame: 1 year
measure: ANA
timeFrame: 3 months
measure: ANA
timeFrame: 6 months
measure: ANA
timeFrame: 1 year
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Manal Hassanien
state: Yes
Study officials:
affiliation: Assiut University
name: Manal Hassanien, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03354546: Development and Validation of a Preoperative Frailty Index Using Health Administrative Data
Official title: Creation, Evaluation and Validation of a Preoperative Frailty Index Using Health Administrative Data: a Population-based Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Frail Elderly Syndrome
Surgery
Outcomes
Predictive Value of Tests
Lead sponsor: Ottawa Hospital Research Institute
Sponsor class: OTHER
First posted: 2017-11-28
Enrollment: 511285
Sex: ALL
Minimum age (years): 66
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All individuals 66 years of older on the day of their surgery

Brief summary: The investigators will create a frailty index using health administrative data available for older people having surgery. The index will be based on the Canadian Study of Health and Aging Frailty Index and standard recommendations for creation of frailty indices.

Detailed description: The investigators will create a frailty index using health administrative data available for older people having surgery. The index will be based on the Canadian Study of Health and Aging Frailty Index and standard recommendations for creation of frailty indices.

Once derived the index will be tested to measure its association with outcomes, as well as its discrimination. Various representations of the frailty index will be tested (primary-as a continuous measure; secondary as a binary, categorical and fractional polynomial variable). Performance in subgroups will also be evaluated,

Eligibility criteria: Inclusion Criteria:

* Having elective or emergency noncardiac surgery

Exclusion Criteria:

* no provincial health insurance number

Primary outcomes:
measure: Survival for One Year After Surgery
timeFrame: Date of surgery to 365 days after surgery
Secondary outcomes:
measure: Institutional Discharge
timeFrame: Date of surgery to date of hospital discharge, or up to one year after surgery (whichever comes first)
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01412346: Health Effects of a Nordic Diet Rich in Plant-based Foods and Fish
Official title: Health Effects of a Nordic Diet Rich in Plant-based Foods and Fish
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Prehypertension
Hypertension
Keywords: human
clinical trial
dietary intervention study
blood pressure
cardiovascular biomarkers
nutritional biomarkers
gene expression
Lead sponsor: Finnish Institute for Health and Welfare
Sponsor class: OTHER_GOV
Collaborators: name: Academy of Finland
name: University of Oslo
First posted: 2011-08-09
Enrollment: 111
Sex: ALL
Minimum age (years): 45
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the effects of a Nordic diet rich in plant-based foods and fish on indicators of cardiovascular disease risk at two different levels of salt intake.

The study is a 20-wk randomized controlled crossover trial. The subjects follow a salt-restricted diet during the study. The study begins with a 4-wk run-in phase for all subjects. After that the subjects are randomly allocated to one of two groups. Group 1 consumes a healthy Nordic low-salt diet enriched with plant-based foods and fish for 16 weeks. Group 2 consumes a low-salt diet for 16 weeks. During the 16 weeks, both groups receive salt and placebo capsules in a double-blind, crossover fashion (8+8 weeks).


Eligibility criteria: Inclusion Criteria:

* prehypertension or hypertension (systolic blood pressure 130-159 mmHg or diastolic blood pressure 85-99 mmHg)

Exclusion Criteria:

* smoking
* regular use of medications
* intestinal disorders
* symptomatic cardiovascular disease
* obesity (BMI\>35 kg/m2)
* vegetarianism
* high intake of alcohol
* allergy to fish
* pregnancy

Primary outcomes:
measure: Change from baseline in systolic and diastolic blood pressure after treatments
timeFrame: 12 and 20 weeks
Secondary outcomes:
measure: Change from baseline in PFA-100 measurements after treatments
timeFrame: 12 and 20 weeks
measure: Change from baseline in biomarkers of cardiovascular disease risk after treatments
timeFrame: 12 and 20 weeks
measure: Change from baseline in nutritional biomarkers after treatments
timeFrame: 12 and 20 weeks
measure: Change from baseline in blood cell gene expression after treatments
timeFrame: 12 and 20 weeks
Other outcomes:
Locations:
city: Helsinki
country: Finland
facility: National Institute for Health and Welfare
Study officials:
affiliation: Finnish Institute for Health and Welfare
name: Iris Erlund, Dr.
role: STUDY_DIRECTOR
affiliation: Finnish Institute for Health and Welfare
name: Antti Jula, Dr.
role: STUDY_DIRECTOR
References:
Clinical trial NCT05244746: Efficacy of Ultrasound Guided Rectus Sheath Block on Post Operative Quality of Recovery
Official title: Efficacy of Ultrasound Guided Rectus Sheath Block Combined With General Anaesthesia on the Postoperative Quality of Recovery Profile in Laparotomy Surgeries, Randomized Control Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postoperative Pain
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
First posted: 2022-02-17
Enrollment: 48
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Effective Postoperative pain management following laparotomy represents a cornerstone in the care of surgical patients. With the growing utilization of Enhanced recovery after surgery protocols (ERAS), a paradigm shift in perioperative care has resulted in reduction of both hospital stay and clinical complications faced by patients.

One important component of successful implementation of ERAS protocol is optimized pain control. It has been shown that opioids have a considerable role in reducing bowel motility in addition; it hinders early mobilization and enteral feeding besides their commonly faced side effects such as nausea and vomiting.

Consequently, ERAS programs encourage the usage of multimodal opioid sparing analgesia which includes neuraxial or regional anesthesia techniques to provide effective pain relief while reducing the opioid related side effects. \[1\]

Regional blocks have remained popular with evidence of superior postoperative pain control when compared with systemic analgesics. Regional anaesthesia techniques have undergone considerable refinement with the advent of ultrasound guidance. Ultrasound visualization of anatomical structures increases both the safety and quality of regional blocks through optimal needle placement. Ultrasound-guided rectus sheath (RS) blocks are an emerging anaesthetic technique providing excellent analgesia after laparotomy. The anatomic characteristics of this block suggest minimal serious complications are likely, and this regional block is particularly useful where epidural is contraindicated


Eligibility criteria: Inclusion Criteria:

1. 18-60 years old patients
2. ASA 1-2 patients
3. Patients undergoing elective midline laparotomy.

Exclusion Criteria:

* 1. refusal to consent, 2. previous laparotomy (subsequently amended to exclude only a laparotomy with a paramedian scar), 3. significant hepatic or renal disease, 4. any condition limiting the use of co-analgesics (diclofenac and acetaminophen), 5. coagulopathy (international normalized ratio: 1.5 ) 6. Patients with body weight \\ 50 kg.

Primary outcomes:
measure: quality of recovery
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Kasr alainy medical school
Study officials:
References: